Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans.

10 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Slushy spares kidney during partial nephrectomy

US researchers report the success and feasibility of a novel method of carrying out partial nephrectomy in kidney patients, using minimally invasive surgery.

20 Dec 2012

Nephron-sparing surgery beats ablation for small renal masses

Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.

17 Dec 2012

Everolimus therapy might treat Myc-driven lymphoma

Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

15 Dec 2012

New technique may allow more kidney cancer patients to avoid conventional open surgery

Urologists at Henry Ford Hospital have developed a new technique that could make minimally invasive robotic partial nephrectomy procedures the norm, rather than the exception for kidney cancer patients. The technique spares the kidney, eliminates long hospital stays and provides better outcomes by giving the surgeon more time to perform the procedure.

14 Dec 2012

Kidney cancer survival rates: an interview with Dr Wong-Ho Chow

There are two major forms of kidney cancer. One is called renal cell cancer, which is an adenocarcinoma that occurs in the renal parenchyma. The other major type is called renal pelvis cancer, which is mostly of transitional cell type and they form in the centre of the kidney where the urine collects.

7 Dec 2012

Researchers discover 29 proteins associated with spread of kidney cancer

Researchers at St. Michael's hospital have identified 29 proteins that are likely to be involved in the spread of kidney cancer. The discovery will help physicians recognize which tumours are going to behave more aggressively and provide those patients with more intensive treatment and closer followup.

7 Dec 2012

Tumors 'not always greatest mortality risk in RCC patients'

Patients with localized solid kidney tumors may be at greater risk for death from non-cancer-related causes before that from disease progression and cancer-related mortality, say US researchers who developed a comorbidity-based risk prediction model.

22 Nov 2012

Kidney tumors may be smarter than previously thought

New research has found there are several different ways that kidney tumours can achieve the same result - namely, grow.

22 Nov 2012

White kidney cancer patients have a survival advantage over blacks

Among patients with the most common form of kidney cancer, whites consistently have a survival advantage over blacks, regardless of patient and tumor characteristics or surgical treatment.

12 Nov 2012

Encouraging results from stereotactic radiosurgery Phase I trial on kidney cancer

A first-of-its-kind clinical trial conducted at University Hospitals (UH) Case Medical Center Seidman Cancer Center has shown encouraging results for the use of stereotactic radiosurgery to treat kidney cancer.

1 Nov 2012

Active surveillance of small kidney masses offers similar cancer outcomes to radical or partial surgery

Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery, with similar overall and cancer specific survival rates, according to a study published in the November issue of the urology journal BJUI.

19 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

Recovery from single-site laparoscopy is less painful for kidney cancer patients

Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery.

28 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012